2seventy bio (TSVT) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 05, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-40791
Entity Registrant Name	2seventy bio, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-3658454
Entity Address, Address Line One	60 Binney Street
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	2142
City Area Code	339
Local Phone Number	499-9300
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	TSVT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,622,368
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001860782
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 270,893	$ 130,414
Marketable securities	106,973	134,643
Prepaid expenses	18,002	9,512
Receivables and other current assets	16,931	16,995
Total current assets	412,799	291,564
Property, plant and equipment, net	35,038	34,913
Fair Value	74,683	97,124
Intangible assets, net	8,774	9,892
Goodwill	12,056	12,056
Operating lease right-of-use assets	270,825	275,534
Restricted cash and other non-current assets	37,746	38,592
Total assets	851,921	759,675
Current liabilities:
Accounts payable	13,647	6,024
Accrued expenses and other current liabilities	58,475	55,410
Operating lease liability, current portion	10,066	9,769
Deferred revenue, current portion	5,000	5,000
Collaboration research advancement, current portion	19,125	22,185
Total current liabilities	106,313	98,388
Deferred revenue, net of current portion	25,762	25,762
Collaboration research advancement, net of current portion	710	1,135
Operating lease liability, net of current portion	269,289	272,446
Other non-current liabilities	2,431	2,122
Total liabilities	404,505	399,853
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized, 0 shares issued and outstanding at March 31, 2022 and December 31, 2021	0	0
Common stock, $0.0001 par value; 200,000 shares authorized, 37,616 and 23,585 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	4	2
Additional paid-in capital	575,421	400,026
Accumulated other comprehensive loss	(2,804)	(712)
Accumulated deficit	(125,205)	(39,494)
Total stockholders’ equity	447,416	359,822
Total liabilities and stockholders’ equity	$ 851,921	$ 759,675

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value per share (in dollars per share)	$ 0.1000	$ 0.1000
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.1000	$ 0.1000
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	37,616,000	23,585,000
Common stock, shares outstanding (in shares)	37,616,000	23,585,000

Condensed Consolidated and Comb

Condensed Consolidated and Combined Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Collaborative arrangement revenue	$ 3,487	$ 1,519
Total revenues	8,429	11,901
Operating expenses:
Research and development	69,245	77,571
Selling, general and administrative	23,861	24,627
Share of collaboration loss	5,352	0
Cost of royalty and other revenue	511	1,704
Change in fair value of contingent consideration	48	369
Total operating expenses	99,017	104,271
Loss from operations	(90,588)	(92,370)
Interest income, net	115	0
Other income, net	4,762	5,174
Loss before income taxes	(85,711)	(87,196)
Income tax (expense) benefit	0	0
Net loss and comprehensive loss	$ (85,711)	$ (87,196)
Net loss per share - basic (in dollars per share)	$ (3.20)	$ (3.73)
Net loss per share - diluted (in dollars per share)	$ (3.20)	$ (3.73)
Weighted-average number of common shares used in computing net loss per share - basic (in shares)	26,751,000	23,369,000
Weighted-average number of common shares used in computing net loss per share - diluted (in shares)	26,751,000	23,369,000
Other comprehensive loss:
Other comprehensive loss, net of tax benefit (expense) of $0.0 million and $0.0 million for the three months ended March 31, 2022 and 2021, respectively.	$ (2,092)	$ 0
Comprehensive loss	(87,803)	(87,196)
Service
Revenue:
Revenue	4,055	5,918
Royalty and other revenue
Revenue:
Revenue	$ 887	$ 4,464

Condensed Consolidated and Co_2

Condensed Consolidated and Combined Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Other Comprehensive Income (Loss), Tax	$ 0	$ 0

Condensed Consolidated and Co_3

Condensed Consolidated and Combined Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock	Net parent investment	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2020		0
Beginning balance at Dec. 31, 2020	$ 74,629	$ 0	$ 74,629	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	17,109		17,109
Transfers from bluebird bio	71,101		71,101
Net loss	(87,196)		(87,196)
Ending balance (in shares) at Mar. 31, 2021		0
Ending balance at Mar. 31, 2021	$ 75,643	$ 0	75,643	0	0	0
Beginning balance (in shares) at Dec. 31, 2021	23,585,000	23,585,000
Beginning balance at Dec. 31, 2021	$ 359,822	$ 2	0	400,026	(712)	(39,494)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock units (in shares)		97,000
Exercise of stock options	1			1
Issuance of common stock for private equity placement (in shares)		13,934,000
Issuance of common stock in private placement, net of issuance costs	165,657	$ 2		165,655
Stock-based compensation	9,739			9,739
Other comprehensive loss	(2,092)				(2,092)
Net loss	$ (85,711)					(85,711)
Ending balance (in shares) at Mar. 31, 2022	37,616,000	37,616,000
Ending balance at Mar. 31, 2022	$ 447,416	$ 4	$ 0	$ 575,421	$ (2,804)	$ (125,205)

Condensed Consolidated and Co_4

Condensed Consolidated and Combined Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (85,711)	$ (87,196)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Change in fair value of contingent consideration	48	369
Depreciation and amortization	3,530	3,676
Stock-based compensation expense	9,739	17,109
Other non-cash items	1,227	69
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(7,768)	2,262
Operating lease right-of-use assets	4,710	3,652
Accounts payable	6,228	4,535
Accrued expenses and other liabilities	280	(1,248)
Operating lease liabilities	(2,860)	(5,639)
Deferred revenue	0	(820)
Collaboration research advancement	(3,487)	(1,519)
Net cash used in operating activities	(74,064)	(64,750)
Cash flows from investing activities:
Purchases of property, plant and equipment	(3,585)	(6,351)
Purchases of marketable securities	(22,450)	0
Proceeds from maturities of marketable securities	70,784	0
Net cash provided by (used in) investing activities	44,749	(6,351)
Cash flows from financing activities:
Transfers from bluebird bio	0	71,101
Proceeds from issuance of common stock in private placement	170,000	0
Proceeds from exercise of stock options and ESPP contributions	99	0
Net cash provided by financing activities	170,099	71,101
Increase (decrease) in cash, cash equivalents and restricted cash	140,784	0
Cash, cash equivalents and restricted cash at beginning of period	163,266	0
Cash, cash equivalents and restricted cash at end of period	304,050	0
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	270,893	0
Restricted cash included in restricted cash and other non-current assets	33,157	0
Total cash, cash equivalents, and restricted cash	304,050	0
Supplemental cash flow disclosures:
Purchases of property, plant and equipment included in accounts payable and accrued expenses	2,925	1,954
Private placement issuance costs included in accounts payable and accrued expenses	$ 4,343	$ 0

Description of the business

Description of the business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the business	Description of the business 2seventy bio, Inc. (the “Company” or “2seventy bio”) was incorporated in Delaware on April 26, 2021 and is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company’s approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop highly innovative, targeted cellular therapies for patients with cancer. The Company is advancing multiple preclinical and clinical programs in oncology and, together with Bristol Myers Squibb (“BMS”), delivering the first FDA-approved CAR T therapy in multiple myeloma, ABECMA (idecabtagene vicleucel, or ide-cel), to patients in the United States. Please refer to Note 9, Collaborative arrangements and strategic partnerships for further discussion of the collaboration with BMS . 2seventy bio Securities Corporation is a wholly-owned subsidiary of the Company which was incorporated in Massachusetts on December 13, 2021 and was granted securities corporation status in Massachusetts for the 2021 tax year. 2seventy bio Securities Corporation has no employees. The separation from bluebird bio, Inc. In January 2021, bluebird bio, Inc. (“bluebird bio”) announced its plans to separate its oncology portfolio and programs from its severe genetic disease portfolio and programs, and spin off its oncology portfolio and programs into a separate, publicly traded company. In furtherance of this plan, on September 30, 2021, bluebird bio’s board of directors approved the distribution of all of the issued and outstanding shares of 2seventy bio common stock on the basis of one share of 2seventy bio common stock for every three shares of bluebird bio common stock issued and outstanding on October 19, 2021, the record date for the distribution. As a result of the distribution, which occurred on November 4, 2021, 2seventy bio became an independent, publicly traded company. On November 3, 2021, the Company also entered into a separation agreement with bluebird bio, which is referred to in this quarterly report as the separation agreement, as well as various other agreements with bluebird bio, including a tax matters agreement, an employee matters agreement, an intellectual property license agreement, a transition services agreement under which 2seventy bio temporarily receives certain services from bluebird bio, and a second transition services agreement under which 2seventy bio temporarily provides certain services to bluebird bio. These agreements also govern certain of 2seventy bio’s relationships with bluebird bio after the separation. For additional information regarding the separation agreement and the other related agreements, refer to Note 13, Related-party transactions and the section captioned “Transactions with Related and Certain Other Parties” in this Quarterly Report on Form 10-Q. Going concern In accordance with Accounting Standards Codification 205-40, Going Concern , the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated and combined financial statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the three months ended March 31, 2022, the Company incurred a net loss of $85.7 million and used $74.1 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years. The Company's continued operations are dependent on its ability to raise additional funding. As of March 31, 2022, the Company had cash, cash equivalents, and marketable securities of $452.5 million. The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these financial statements. The

Summary of significant accounti

Summary of significant accounting policies and basis of presentation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies and basis of presentation	Summary of significant accounting policies and basis of presentation Significant accounting policies The significant accounting policies used in preparation of these condensed consolidated and combined financial statements for the three months ended March 31, 2022 and 2021 are consistent with those discussed in Note 2 to the consolidated and combined financial statements for the year ended December 31, 2021 included in the Company’s 2021 Annual Report on Form 10-K. Basis of presentation The Company did not operate as a separate, stand-alone entity prior to its separation from bluebird bio. Accordingly, the Company’s consolidated and combined statements of operations and comprehensive loss, stockholders’ equity and cash flows for the three months ended March 31, 2021, have been prepared on a carve out basis, derived from bluebird bio’s consolidated financial statements and accounting records. The accompanying condensed consolidated and combined financial statements reflect the historical results of the operations, financial position and cash flows of the Company and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as included in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The historical results of operations and cash flows of 2seventy bio presented in these condensed consolidated and combined financial statements for periods prior to the separation may not be indicative of what they would have been had 2seventy bio operated as an independent, stand-alone entity for those periods. The historical results of operations, financial position and cash flows of 2seventy bio presented in these condensed consolidated and combined financial statements for periods subsequent to the separation are not necessarily indicative of 2seventy bio's future results of operations, financial position and cash flows. In the opinion of management, the unaudited interim condensed consolidated and combined financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position and the results of its operations for the interim periods presented. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates and judgments are used in the following areas, among others: allocations of revenue, expenses, assets and liabilities from bluebird bio's historical consolidated financial statements to the Company for periods prior to the separation, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.

Marketable securities

Marketable securities	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable securities	Marketable securities The following table summarizes the marketable securities held at March 31, 2022 and December 31, 2021 (in thousands): Amortized Unrealized gains Unrealized losses Fair Value March 31, 2022 U.S. government agency securities and $ 140,192 $ 3 $ (2,028) $ 138,167 Corporate bonds 33,803 — (136) 33,667 Commercial paper 9,822 — — 9,822 Total $ 183,817 $ 3 $ (2,164) $ 181,656 December 31, 2021 U.S. government agency securities and $ 128,899 $ — $ (507) $ 128,392 Corporate bonds 49,368 — (58) 49,310 Commercial paper 54,065 — — 54,065 Total $ 232,332 $ — $ (565) $ 231,767 No available-for-sale debt securities held as of March 31, 2022 or December 31, 2021 had remaining maturities greater than five years.

Fair value measurements

Fair value measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (in thousands): Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) March 31, 2022 Assets: Cash and cash equivalents $ 270,893 $ 270,893 $ — $ — Marketable securities: U.S. government agency securities and treasuries 138,167 — 138,167 — Corporate bonds 33,667 — 33,667 — Commercial paper 9,822 — 9,822 — Total assets $ 452,549 $ 270,893 $ 181,656 $ — Liabilities: Contingent consideration $ 1,996 $ — $ — $ 1,996 Total liabilities $ 1,996 $ — $ — $ 1,996 December 31, 2021 Assets: Cash and cash equivalents $ 130,414 $ 130,414 $ — $ — Marketable securities: U.S. government agency securities and treasuries 128,392 — 128,392 — Corporate bonds 49,310 — 49,310 — Commercial paper 54,065 — 54,065 — Total assets $ 362,181 $ 130,414 $ 231,767 $ — Liabilities: Contingent consideration $ 1,948 $ — $ — $ 1,948 Total liabilities $ 1,948 $ — $ — $ 1,948 Accrued interest receivable on the Company's available-for-sale debt securities totaled $0.3 million as of March 31, 2022. No accrued interest receivable was written off during the three months ended March 31, 2022. The Company determined that there was no material change in the credit risk of the above investments during the three months ended March 31, 2022. As such, an allowance for credit losses was not recognized. As of March 31, 2022, the Company does not intend to sell such securities and it is not more likely than not that the Company will be required to sell the securities before recovery of their amortized cost bases. Contingent consideration In connection with bluebird bio's prior acquisition of Precision Genome Engineering, Inc. (“Pregenen”), the Company may be required to pay future consideration that is contingent upon the achievement of certain commercial milestone events. Contingent consideration is measured at fair value and is based on significant unobservable inputs, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an on-going basis as additional data impacting the assumptions is obtained. Future changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the condensed consolidated and combined statements of operations and comprehensive loss. In the absence of new information related to the probability of milestone achievement, changes in fair value will reflect changing discount rates and the passage of time. Contingent consideration is included in other non-current liabilities on the condensed consolidated balance sheets. The table below provides a roll-forward of fair value of the Company’s contingent consideration obligations that include Level 3 inputs (in thousands): For the three months ended March 31, 2022 Beginning balance $ 1,948 Additions — Changes in fair value 48 Payments — Ending balance $ 1,996 Please refer to Note 8, Commitments and contingencies, for further information.

Property, plant and equipment,

Property, plant and equipment, net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment, net, consists of the following (in thousands): As of March 31, 2022 As of December 31, 2021 Laboratory equipment $ 33,065 $ 31,710 Leasehold improvements 26,709 28,479 Office equipment 6,080 6,080 Construction-in-progress 5,515 3,462 Computer equipment and software 5,260 5,260 Total property, plant and equipment 76,629 74,991 Less accumulated depreciation and amortization (41,591) (40,078) Property, plant and equipment, net $ 35,038 $ 34,913 North Carolina manufacturing facility In July 2021, bluebird bio and National Resilience, Inc. ("Resilience") announced a strategic manufacturing collaboration aimed to accelerate the early research, development, and delivery of cell therapies. Agreements related to the collaboration were executed in September 2021. As part of the agreement, Resilience acquired bluebird bio's North Carolina manufacturing facility and retained all staff employed at the site. As a result, bluebird bio disposed of $111.2 million of net assets, primarily consisting of the building and laboratory equipment. Prior to its disposal by bluebird bio, the North Carolina manufacturing facility was expected to be attributed to the Company as part of the separation and, accordingly, the manufacturing facility was included within the Company’s financial statements prior to its disposal. The disposition of the net assets of the North Carolina manufacturing facility was reflected as a transfer to bluebird bio via net parent investment as a result of bluebird bio’s sale of such facility. Please refer to Note 9, Collaborative arrangements and strategic partnerships , for further discussion regarding the strategic manufacturing collaboration with Resilience.

Accrued expenses and other curr

Accrued expenses and other current liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following (in thousands): As of March 31, 2022 As of December 31, 2021 Employee compensation $ 14,796 $ 24,655 Collaboration research costs 14,082 2,576 Manufacturing costs 11,097 5,459 Royalties 4,146 6,768 Professional fees 1,942 1,688 Clinical and contract research organization costs 1,938 3,229 Property, plant, and equipment 1,311 2,241 Separation related costs 818 762 Other 8,345 8,032 Total accrued expenses and other current liabilities $ 58,475 $ 55,410

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases The Company leases certain office and laboratory space, primarily located in Cambridge, Massachusetts and Seattle, Washington, that was attributed to it in connection with the separation. There have been no material changes to the lease obligations from those disclosed in Note 7, Leases , to the consolidated and combined financial statements included in the Company's 2021 Annual Report on Form 10-K.

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Contingent consideration related to business combinations On June 30, 2014, bluebird bio acquired Pregenen. All assets, liabilities and future obligations related to the Pregenen acquisition, including the resulting goodwill and contingent consideration, were assumed by the Company in connection with the separation. As of March 31, 2022, the Company may be required to make up to $99.9 million in contingent cash payments to the former equity holders of Pregenen upon the achievement of certain commercial milestones related to the Pregenen technology. In accordance with accounting guidance for business combinations, contingent consideration liabilities are required to be recognized on the condensed consolidated balance sheets at fair value. Estimating the fair value of contingent consideration requires the use of significant assumptions primarily relating to probabilities of successful achievement of certain clinical and commercial milestones, the expected timing in which these milestones will be achieved and discount rates. The use of different assumptions could result in materially different estimates of fair value. Other funding commitments Certain agreements that were assigned by bluebird bio to the Company in connection with the separation relate principally to licensed technology and may require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specified products. These agreements include the collaboration agreements entered into with BMS and Regeneron Pharmaceuticals, Inc. ("Regeneron") and the agreements entered into with Resilience, all of which were assigned to the Company in connection with the separation. Additionally, to the extent an agreement relating to licensed technology was not assigned to the Company, bluebird bio entered into a sublicense with the Company, which may require the Company to make future milestone and/or royalty payments. Please refer to Note 9, Collaborative arrangements and strategic partnerships , for further information on the BMS, Regeneron and Resilience agreements and to Note 10, Royalty and other revenue , for further information on license agreements. Based on the Company's development plans as of March 31, 2022, the Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. When the achievement of these milestones or sales has not occurred, such contingencies are not recorded in the Company’s financial statements. As further discussed in Note 9, Collaborative arrangements and strategic partnerships , BMS assumed responsibility for amounts due to licensors as a result of any future ex-U.S. sales of ABECMA®. Concurrent with the sale of the manufacturing facility in Durham, North Carolina, bluebird bio also entered into a commercial supply agreement and a development manufacturing supply agreement with Resilience. Certain rights and obligations under the asset purchase agreement and certain of the ancillary agreements, including the commercial supply agreement and the development manufacturing supply agreement, among others, were assigned by bluebird bio to 2seventy bio on November 4, 2021 upon the separation of 2seventy bio from bluebird bio. The assignments under the asset purchase agreement and the development manufacturing supply agreement commit the Company to reimburse Resilience for an amount equal to 50% of the net operating losses of and relating to the manufacturing facility’s business incurred during the twelve-month period ending on the first anniversary of the closing of the transaction, as calculated in accordance with the asset purchase agreement, subject to a cap of $15.0 million. As of March 31, 2022, the Company has accrued $8.0 million related to the net operating losses of Resilience. In exchange, under the terms of the development manufacturing supply agreement, the Company will receive up to eight batches of lentiviral vector during the twelve-month period ending on the first anniversary of the closing of the transaction. The Company has therefore committed to a minimum purchase of at least the Company's 50% share of the net operating losses during the twelve-month period ending on the first anniversary of the closing of the transaction. Please refer to Note 9, Collaborative arrangements and strategic partnerships , for further discussion. Additionally, 2seventy bio is party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in future minimum purchase commitments from those disclosed in Note 8, Commitments and Contingencies , to the consolidated and combined financial statements included in the Company's 2021 Annual Report on Form 10-K. Litigation From time to time, the Company expects to be party to various claims and complaints arising in the ordinary course of business. However, the Company is not currently a party to any litigation or legal proceedings that, in the opinion of its management, are probable of having a material adverse effect on its business. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners. In addition, pursuant to the separation agreement, the Company indemnifies, holds harmless, and agrees to reimburse bluebird bio for its indemnification obligations with respect to the Company’s business partners, relating to the Company’s business or arising out of the Company’s activities, in the past or to be conducted in the future. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Management does not believe that any ultimate liability resulting from any of these claims will have a material adverse effect on its results of operations, financial position, or liquidity. However, management cannot give any assurance regarding the ultimate outcome of any claims, and their resolution could be material to operating results for any particular period. The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws and indemnification agreements entered into with each of its directors and officers. The term of the indemnification period will last as long as a director or officer may be subject to any proceeding arising out of acts or omissions of such director or officer in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company holds director and officer liability insurance.

Collaborative arrangements and

Collaborative arrangements and strategic partnerships	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative arrangements and strategic partnerships	Collaborative arrangements and strategic partnerships To date, the Company’s service and collaborative arrangement revenue has been primarily generated from collaboration arrangements with BMS and Regeneron, each as further described below. These agreements were assumed by the Company in connection with the separation. Bristol-Myers Squibb BMS Collaboration Agreement In March 2013, bluebird bio entered into a collaboration agreement with BMS. The details of the collaboration agreements and the payments the Company has received, and is entitled to receive, are further described in Note 10, Collaborative arrangements and strategic partnerships , to the consolidated and combined financial statements included in the Company's 2021 Annual Report on Form 10-K. During the first quarter of 2022, there have been no changes to the terms of the collaboration agreement with BMS. ABECMA Under the collaboration agreement with BMS, the Company shares equally in the profit and loss related to the development and commercialization of ide-cel in the United States. The Company has no remaining financial rights with respect to the development or commercialization of ide-cel outside of the United States. The Company accounts for its collaborative arrangement efforts with BMS in the United States within the scope of ASC 808 given that both parties are active participants in the activities and both parties are exposed to significant risks and rewards dependent on the commercial success of the activities. The calculation of collaborative activity to be recognized for joint ide-cel efforts in the United States is performed on a quarterly basis and is independent of previous quarterly activity. This may result in fluctuations between revenue and expense recognition period over period, depending on the varying extent of effort performed by each party during the period. The Company recognizes revenue related to the combined unit of accounting for the ex-U.S. license and lentiviral vector manufacturing services under Topic 606. Ide-cel U.S. Share of Collaboration Profit or Loss The U.S. commercial and development activities under the Amended Ide-Cel CCPS are within the scope of ASC 808. On a quarterly basis, the Company determines its share of collaboration profit or loss for commercial activities (i.e., commercial sales of ABECMA by BMS). The Company’s share of any collaboration profit for commercial activities is recognized as collaborative arrangement revenue and its share of any collaboration loss for commercial activity is recognized as an operating expense and classified as share of collaboration loss on the Company's condensed consolidated and combined statement of operations and comprehensive loss. The Company’s share of collaboration loss from commercial activities was $5.4 million and $0.0 million for the three months ended March 31, 2022 and March 31, 2021, respectively. ABECMA was approved for commercial sale in the U.S. in March 2021 and commercial sales did not begin until April 2021. Accordingly, there is no collaboration profit or loss on commercial activities for the three months ended March 31, 2021. The amounts reported for the three months ended March 31, 2022 represent the Company’s share of BMS’ ABECMA product revenue, cost of goods sold, and selling costs, along with reimbursement by BMS of commercial costs incurred by the Company, and exclude expenses related to ongoing development, which are separately reflected in the condensed consolidated and combined statements of operations and comprehensive loss as described below. The Company is also responsible for equally sharing in the ongoing ide-cel research and development activities being conducted by BMS in the United States as BMS continues conducting ongoing clinical studies to support the use of ABECMA in earlier lines of therapy. The net amount owed to BMS for research and development activities determined on a quarterly basis is classified as research and development expense on the condensed consolidated and combined statement of operations and comprehensive loss. If BMS is obligated to reimburse the Company because the Company’s research and development costs exceeds BMS’ research and development costs in a particular quarterly period, the net amount is recorded as collaborative arrangement revenue. The following table summarizes the amounts associated with the research activities under the collaboration included in research and development expense or recognized as collaborative arrangement revenue for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Net expense $ (6,893) $ (16,825) Ide-cel ex-U.S. Service Revenue The Company accounts for any ex-U.S. activities under the Amended Ide-cel CCPS pursuant to ASC 606. The following table summarizes the revenue recognized related to ide-cel ex-U.S. activities for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 ASC 606 ide-cel license and manufacturing revenue - ex-U.S. $ 2,790 $ 5,104 bb21217 In addition to the activities related to ide-cel, BMS previously exercised its option to obtain an exclusive worldwide license to develop and commercialize bb21217, the second product candidate under the collaboration arrangement with BMS which is further described in Note 10, Collaborative arrangements and strategic partnerships , to the consolidated and combined financial statements included in the Company's 2021 Annual Report on Form 10-K. Under the collaboration arrangement with BMS, the Company has an option to co-develop and co-promote bb21217 within the United States. However, following completion of the CRB-402 clinical trial, and based in part on the strength of ABECMA clinical data and commercial sales to date, in January 2022 the Company, along with BMS, evaluated its plans with respect to bb21217 and does not expect to co-develop and co-promote bb21217. Because the Company does not intend to exercise this option, it expects to receive an additional fee in the amount of $10.0 million from BMS pursuant to the terms of the collaboration arrangement. Under this scenario, there would be no change to the U.S. milestones and royalties for U.S. sales of bb21217, for which the Company would be eligible to receive. All of the remaining development, regulatory, and commercial milestones related to U.S. development, regulatory and commercialization activities are fully constrained and are therefore excluded from the transaction price. The transaction price associated with the collaboration arrangement consists of $31.0 million of upfront payments and option payments received from BMS and $1.8 million in variable consideration which represents reimbursement to be received from BMS for manufacturing vector and associated payloads through development which has not yet been received. The Company has identified two performance obligations with respect to the arrangement with BMS. The initial performance obligation was for research and development services that were substantially completed in September 2019, associated with the initial phase 1 clinical trial of bb21217. The Company allocated $5.4 million of consideration to the research and development services performance obligation and fully recognized the consideration through September 2019. The other performance obligation relates to a combined performance obligation for the bb21217 license and vector manufacturing services through development, and the remaining $27.4 million in consideration was allocated to this combined performance obligation. The Company will satisfy this combined performance obligation as the bb21217 manufacturing services are performed. As of March 31, 2022, the Company has not commenced manufacturing and the full amount of the allocated transaction price remains unsatisfied. The Company had $25.8 million of deferred revenue as of March 31, 2022 and December 31, 2021 associated with the combined performance obligation consisting of the bb21217 license and manufacturing services. Contract assets and liabilities – ide-cel and bb21217 The Company receives payments from its collaborative partners based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under these arrangements. A contract asset is a conditional right to consideration in exchange for goods or services that the Company has transferred to a customer. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The following table presents changes in the balances of the Company’s BMS receivables and contract liabilities during the three months ended March 31, 2022 (in thousands): Balance at December 31, 2021 Additions Deductions Balance at March 31, 2022 Receivables $ 652 $ — $ (652) $ — Contract liabilities: Deferred revenue $ 25,762 $ — $ — $ 25,762 The decrease in the receivables balance for the three months ended March 31, 2022 is driven by amounts paid to the Company from BMS in the period under the settlement terms of the collaboration agreement. Regeneron Regeneron Collaboration Agreement In August 2018, bluebird bio entered into a Collaboration Agreement (the “Regeneron Collaboration Agreement”) with Regeneron pursuant to which the parties will apply their respective technology platforms to the discovery, development, and commercialization of novel immune cell therapies for cancer. In August 2018, following the completion of required regulatory reviews, the Regeneron Collaboration Agreement became effective. As noted above, the agreement was assumed by the Company in connection with the separation. Under the terms of the agreement, the parties will leverage Regeneron’s proprietary platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors directed against tumor-specific proteins and peptides and the Company will contribute its field-leading expertise in gene therapy. In accordance with the Regeneron Collaboration Agreement, the parties jointly selected six initial targets and intend to equally share the costs of research up to the point of submitting an IND application for a potential gene therapy product directed to a particular target. Additional targets may be selected to add to or replace any of the initial targets during the five-year research collaboration term as agreed to by the parties. Regeneron will accrue a certain number of option rights exercisable against targets as the parties reach certain milestones under the terms of the agreement. Upon the acceptance of an IND for the first product candidate directed to a target, Regeneron will have the right to exercise an option for co-development/co-commercialization of product candidates directed to such target on a worldwide or applicable opt-in territory basis, with certain exceptions. Where Regeneron chooses to opt-in, the parties will share equally in the costs of development and commercialization and will share equally in any profits or losses therefrom in applicable opt-in territories. Outside of the applicable opt-in territories, the target becomes a licensed target and Regeneron would be eligible to receive, with respect to any resulting product, milestone payments of up to $130.0 million per product and royalties on net sales outside of the applicable opt-in territories at a rate ranging from the mid-single digits to low-double digits. A target would also become a licensed target in the event Regeneron does not have an option to such target, or Regeneron does not exercise its option with respect to such target. Either party may terminate a given research program directed to a particular target for convenience, and the other party may elect to continue such research program at its expense, receiving applicable cross-licenses. The terminating party will receive licensed product royalties and milestone payments on the potential applicable gene therapy products. Where the Company terminates a given research program for convenience, and Regeneron elects to continue such research program, the parties will enter into a transitional services agreement. Under certain conditions, following its opt-in, Regeneron may terminate a given collaboration program and the Company may elect to continue the development and commercialization of the applicable potential gene therapy products as licensed products. Regeneron Share Purchase Agreement A Share Purchase Agreement (“SPA”) was entered into by bluebird bio and Regeneron in August 2018. In August 2018, on the closing date of the transaction, bluebird bio issued Regeneron 0.4 million shares of bluebird bio’s common stock, subject to certain restrictions, for $238.10 per share, or $100.0 million in the aggregate. The purchase price represents $63.0 million worth of common stock plus a $37.0 million premium, which represents a collaboration research advancement, or credit to be applied to Regeneron’s initial 50 percent funding obligation for collaboration research, after which the collaborators will continue to fund ongoing research equally. The collaboration research advancement only applies to pre-IND research activities and is not refundable or creditable against post-IND research activities for any programs where Regeneron exercises its opt-in rights. Accounting analysis – Regeneron At the commencement of the arrangement, two units of accounting were identified, which are the issuance of 0.4 million shares of bluebird bio’s common stock and joint research activities during the five-year research collaboration term. The Company determined the total transaction price to be $100.0 million, which comprises $54.5 million attributed to the bluebird bio equity sold to Regeneron and $45.5 million attributed to the joint research activities. In determining the fair value of the bluebird bio common stock at closing, the Company considered the closing price of the bluebird bio common stock on the closing date of the transaction and included a lack of marketability discount because Regeneron received shares subject to certain restrictions. The Company analyzed the joint research activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, for the collaboration research performed prior to submission of an IND application for a potential gene therapy product, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities and will share equally in these costs through IND. Additionally, Regeneron and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. The $45.5 million attributed to the joint research activities includes the $37.0 million creditable against amounts owed to the Company by Regeneron. The collaboration research advancement will be reduced over time for amounts due to the Company by Regeneron as a result of the parties agreeing to share in the costs of collaboration research equally. The remainder of the amount attributed to the joint research activities will be recognized over the five-year research collaboration term. Consistent with its collaboration accounting policy, the Company will recognize collaboration revenue or research and development expense related to the joint research activities in future periods depending on the amounts incurred by each party in a given reporting period. That is, if the Company’s research costs incurred exceed those research costs incurred by Regeneron in a given quarter, the Company will record collaboration revenue and reduce the original $37.0 million advance by the amount due from Regeneron until such advancement is fully utilized, after which the Company would record an amount due from Regeneron. If Regeneron’s research costs incurred exceed those research costs incurred by the Company in a given quarter, the Company will record research and development expense and record a liability for the amount due to Regeneron. As of March 31, 2022 and December 31, 2021, the Company has $19.8 million and $23.3 million, respectively, of the amount attributed to the joint research activities remaining to be recognized, which is classified as collaboration research advancement, current portion and collaboration research advancement, net of current portion on the condensed consolidated balance sheets. The Company recognized $3.5 million and $1.5 million of collaborative arrangement revenue from the Regeneron Collaboration Agreement during the three months ended March 31, 2022, and 2021, respectively. Resilience Background In July 2021, bluebird bio and Resilience US, Inc. (formerly known as Resilience Boston, Inc.), an affiliate of Resilience, signed an Asset Purchase Agreement (the “Agreement”). As part of the Agreement, and upon the closing of the transaction which occurred in September 2021, Resilience acquired bluebird bio's lentiviral vector manufacturing facility located in Durham, North Carolina and retained staff employed at the site. In exchange, bluebird bio received $110.3 million for the facility and related fixed assets. Upon the completion of the separation in November 2021, certain rights and obligations under the Agreement and certain Ancillary Agreements were assigned by bluebird bio to 2seventy bio, with 2seventy bio assuming all rights and obligations these agreements convey. Upon closing, bluebird bio entered into certain ancillary agreements, including two manufacturing agreements and a license agreement (the “License Agreement”), among others (together referred to as the “Ancillary Agreements”). One manufacturing agreement will support the future manufacturing of lentiviral vector for the Company’s commercial product in collaboration with BMS, ide-cel (the “Commercial Supply Agreement”), while the other will support ongoing manufacturing for lentiviral vector for the Company's development candidates (the “Development Manufacturing Supply Agreement”). The Company also agreed to reimburse Resilience for an amount equal to 50% of the net operating losses of and relating to the manufacturing facility’s business incurred during the twelve-month period ending on the first anniversary of the closing of the transaction, as calculated in accordance with the Agreement, subject to a cap of $15.0 million. In exchange, under the terms of the Development Manufacturing Supply Agreement, the Company will receive up to eight batches of lentiviral vector during the twelve-month period ending on the first anniversary of the closing of the transaction. The License Agreement grants Resilience a worldwide, co-exclusive license to intellectual property controlled by the Company to perform Resilience’s obligations and exercise Resilience’s rights under the supply agreements, and a worldwide, nonexclusive right to offer certain manufacturing services to third-party customers under certain of the Company's intellectual property. Under the terms of the License Agreement, the Company may receive a high single-digit to low double-digit percentage tiered royalty based on Resilience’s gross margins for transactions entered into with parties other than the Company in which the Company's proprietary intellectual property is utilized as part of such transaction. Under the Commercial Supply Agreement, the Company will pay fully burdened manufacturing cost plus a markup for production of vector. Under the Development Manufacturing Supply Agreement, services, manufacture, and delivery of batches of lentiviral vector during the first twelve months from the execution of this agreement will be free of cost, as the costs of these services are represented by the net operating loss sharing arrangement outlined within the Agreement. As such, the Company has committed to a minimum purchase of at least the Company's 50% share of the net operating losses during the first twelve months from the execution of such agreement. After the first twelve months, the Company will pay Resilience the fully burdened manufacturing cost plus a markup for production of vector. Accounting analysis - Resilience Since the January 2021 announcement by bluebird bio of its plans to separate and spin-off of 2seventy bio from its severe genetic disease portfolio and programs, the manufacturing facility was expected to be assigned to 2seventy bio and was therefore accounted for within the 2seventy bio carve-out financial statements. The disposition of the net assets of the manufacturing facility previously assigned to 2seventy bio has been reflected as a transfer to bluebird bio via net parent investment as a result of bluebird bio’s sale of such facility. 2seventy bio is not a party to the sale of the manufacturing facility and, therefore, did not recognize any gain or loss arising from the transaction. Future royalty payments under the License Agreement (which was assigned to the Company as previously described) are considered part of the consideration associated with the disposition of the manufacturing facility. In accordance with ASC 450, the Company will recognize future royalties received under the License Agreement in the period the contingencies are resolved as an adjustment to the consideration received as other income in the condensed consolidated and combined statements of operations and comprehensive loss. Novo Nordisk Novo Collaboration and License Agreement On December 23, 2021, the Company entered into a Collaboration and License Agreement (the “Novo Collaboration Agreement”) with Novo Nordisk A/S (“Novo”) for the discovery, development, and commercialization of a potential new gene therapy in hemophilia A. The Company and Novo have agreed to develop an initial research program with the goal of researching and developing a lead candidate directed to hemophilia A. The Company will provide Novo with research licenses to support the companies’ activities during the initial research program and an option to enable Novo to obtain an exclusive license to commercialize the product derived from or containing compounds developed during the initial research program. Under the terms of the Novo Collaboration Agreement, Novo agreed to pay the Company: • a non-refundable, non-creditable upfront payment of $5.0 million; • $15.0 million upon achievement of certain scientific milestones during the initial research program, or $9.0 million should Novo decide to continue the initial research program without achieving the scientific milestones; • up to $26.0 million of exclusive license fees for the development, manufacture, and commercialization of the product should Novo exercise its option; and, • up to $72.0 million in development and commercialization milestones. Novo also agreed to reimburse the Company for research costs incurred in connection with the initial research program up to a mutually agreed upon amount, initially budgeted at $6.7 million. If Novo exercises its option to obtain a license to commercialize the product developed during the initial research program, the Company is also eligible to receive mid-single digit royalties on product sales on a country-by-country and product-by-product basis, subject to certain royalty step-down provisions set forth in the agreement. Accounting Analysis - Novo The Company concluded that Novo is a customer, and as such, the arrangement falls within the scope of Topic 606. The Company identified two performance obligations consisting of (i) the research license and research and development services to be provided during the initial research program and (ii) a material right related to Novo’s option to obtain an exclusive license for the development, manufacture, and commercialization of the product developed during the initial research program. The Company determined that the research license and research and development services promises were not separately identifiable and were not distinct or distinct within the context of the contract due to the specialized nature of the services to be provided by 2seventy, specifically with respect to the Company’s expertise related to gene therapy and the interdependent relationship between the promises. The material right is considered a separate performance obligation pursuant to the provisions of Topic 606. At contract inception, the Company determined the unconstrained transaction price was $11.7 million, consisting of the $5.0 million in up-front consideration and the $6.7 million in reimbursement for the research and development services. Variable consideration associated with the scientific milestones was fully constrained due to the uncertainty associated with the outcome of the research efforts under the initial research program. The Company allocated $6.7 million of the transaction price to the research services and $5.0 million to the material right using a relative selling price methodology. Management will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and adjust the transaction price as necessary.

Royalty and other revenue

Royalty and other revenue	3 Months Ended
	Mar. 31, 2022
License And Royalty Revenue [Abstract]
Royalty and other revenue	Royalty and other revenue bluebird bio has out-licensed intellectual property to various third parties. Under the terms of these agreements, some of which were assumed by the Company in connection with the separation, bluebird bio and the Company may be entitled to royalties and milestone payments. The Company recognized $0.9 million and $4.5 million of royalty and other revenue in the three months ended March 31, 2022 and 2021, respectively. Novartis Pharma AG In April 2017, bluebird bio entered into a worldwide license agreement with Novartis. Under the terms of the agreement, Novartis non-exclusively licensed certain patent rights related to lentiviral vector technology to develop and commercialize CAR T cell therapies for oncology, including Kymriah (formerly known as CTL19), Novartis’s anti-CD19 CAR T therapy. The agreement was assumed by the Company in connection with the separation. Beginning in the fourth quarter of 2017, bluebird bio began receiving royalties from sales of tisagenlecleucel under the agreement. This license agreement was terminated effective March 2021, at which point in time Novartis was no longer required to make royalty or other payments on net sales of tisagenlecleucel or any future products. Royalty revenue recognized from sales of tisagenlecleucel is included within royalty and other revenue in the condensed consolidated and combined statement of operations and comprehensive loss. Juno Therapeutics In May 2020, bluebird bio entered into a non-exclusive license agreement with Juno Therapeutics, Inc. (“Juno”), a wholly-owned subsidiary of BMS, related to lentiviral vector technology to develop and commercialize CD-19-directed CAR T cell therapies. The agreement was assumed by the Company in connection with the separation. Upon regulatory approval of lisocabtagene maraleucel during the first quarter of 2021, bluebird bio received a $2.5 million milestone payment from Juno, which is included within royalty and other revenue in the Company’s condensed consolidated and combined financial statements. Royalty revenue recognized from sales of

Equity

Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Equity	EquityIn March 2022, the Company entered into stock purchase agreements with certain investors, pursuant to which the Company agreed to sell and issue, in a private placement, an aggregate of 13,934,427 shares of the Company’s common stock at a purchase price per share of $12.20. This resulted in aggregate net proceeds to the Company of approximately $165.7 million, after deducting placement agent fees and other offering expenses payable by the Company.

Stock-based compensation

Stock-based compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation In connection with 2seventy’s separation from bluebird bio on November 4, 2021, under the provisions of the existing plans, the outstanding bluebird bio equity awards were adjusted in accordance with the terms of the employee matters agreement (equitable adjustment) to preserve the intrinsic value of the awards immediately before and after distribution. Refer to Note 13, Stock-based compensation , to the consolidated and combined financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 for details on the conversion methodology of the equity awards. In October 2021, the Company’s board of directors adopted the 2021 Stock Option and Incentive Plan (“2021 Plan”) which allows for the granting of incentive stock options, non-qualified stock options, restricted stock units (“RSUs”), performance-based restricted stock units (“PRSUs”), and restricted stock awards to 2seventy bio’s employees, members of the board of directors, and consultants of 2seventy bio, including those who became employees of the Company in connection with the separation. Shares of the Company’s common stock underlie all awards granted under the 2021 Plan. Stock-based compensation expense For periods prior to the separation, stock-based compensation expense was allocated to the Company using a combination of specific identification and time spent on projects at various levels of the organization, which management believes are consistent and reasonable. Post separation, stock-based compensation expense includes compensation cost related to 2seventy equity awards held by its employees as well as bluebird bio equity awards issued upon separation to its employees. Stock-based compensation expense recognized by award type was as follows (in thousands): For the three months ended March 31, 2022 2021 Stock options $ 4,404 $ 7,586 Restricted stock units 5,314 7,205 Employee stock purchase plan and other 21 2,318 $ 9,739 $ 17,109 Stock-based compensation expense by classification included within the condensed consolidated and combined statements of operations and comprehensive loss was as follows (in thousands): For the three months ended March 31, 2022 2021 Research and development $ 4,218 $ 9,431 Selling, general and administrative 5,521 7,678 $ 9,739 $ 17,109 Employee Stock Purchase Plan During the three months ended March 31, 2022, no shares of common stock were issued under the Company’s 2021 Employee Stock Purchase Plan.

Related-party transactions

Related-party transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related-party transactions	Related-party transactions Relationship with bluebird bio Following the separation, bluebird bio is considered a related party. In connection with the separation, the Company entered into a separation agreement (the “Separation Agreement”) with bluebird bio, dated as of November 3, 2021, that, among other things, set forth bluebird bio’s agreements with 2seventy bio regarding the principal actions to be taken in connection with the separation, including the distribution. The effective time of the distribution was 12:01 a.m. on November 4, 2021. The Separation Agreement identifies assets transferred to, liabilities assumed by and contracts assigned to 2seventy bio as part of the separation, and it provides for when and how these transfers, assumptions and assignments occur. The purpose of the Separation Agreement is to provide 2seventy bio and bluebird bio with assets to operate their respective businesses and retain or assume liabilities related to those assets. Each of 2seventy bio and bluebird bio agreed to releases, with respect to pre-separation claims, and cross indemnities with respect to post-separation claims, that are principally designed to place financial responsibility for the obligations and liabilities allocated to 2seventy bio under the Separation Agreement with 2seventy bio and financial responsibility for the obligations and liabilities allocated to bluebird bio under the Separation Agreement. bluebird bio and 2seventy bio are also each subject to mutual 12-month employee non-solicit and non-hire restrictions, subject to certain customary exceptions. In accordance with the Separation Agreement with bluebird bio, there were certain other transactions and adjustments post-Separation between the Company and bluebird bio. For the three months ended March 31, 2022, the Company recorded a net receivable to operating income of $2.9 million related to the Separation Agreement. The Company and bluebird bio also entered into a tax matters agreement, dated as of November 3, 2021, governing bluebird bio’s and 2seventy bio's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the distribution and certain related transactions to qualify as tax-free for U.S. federal income tax purposes, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and assistance and cooperation in respect of tax matters). In connection with the separation, the Company also entered into an employee matters agreement with bluebird bio, dated as of November 3, 2021. The employee matters agreement allocates assets, liabilities and responsibilities relating to the employment, compensation and employee benefits of bluebird bio and 2seventy bio employees, and other related matters, in connection with the separation, including the treatment of outstanding bluebird bio incentive equity awards and certain retirement and welfare benefit obligations. The employee matters agreement generally provides that, unless otherwise specified, 2seventy bio is responsible for liabilities associated with employees who transfer to 2seventy bio and employees whose employment terminated prior to the distribution but who primarily supported the 2seventy bio business, and bluebird bio is responsible for liabilities associated with other employees, including employees retained by bluebird bio. Included in the agreement are also specific clauses relating to liabilities assumed by bluebird bio for the costs incurred prior to the separation. For the three months ended March 31, 2022, the Company recorded a net charge to operating expense of $0.2 million for costs stipulated by the employee matters agreement. The Company and bluebird bio also entered into an intellectual property license agreement on November 3, 2021, pursuant to which each party granted a license to certain intellectual property and technology to the other. bluebird bio granted 2seventy bio a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property to allow 2seventy bio to use such intellectual property in connection with 2seventy bio's ongoing and future research and development activities and product candidates. 2seventy bio granted bluebird bio a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property for use in bluebird bio’s existing products and product candidates. Such licenses between the parties generally allow current or future uses of the intellectual property in connection with each party's respective fields. Charges associated to the intellectual property license agreement commenced in 2022. For the three months ended March 31, 2022, the Company recorded immaterial costs associated with this agreement. The Company and bluebird bio entered into two transition services agreements on November 3, 2021, pursuant to which bluebird bio will provide 2seventy bio with corporate and shared services and resources related to corporate functions such as finance, human resources, internal audit, research and development, financial reporting, and information technology, and to which 2seventy bio will provide certain services to bluebird bio, each for an initial term of two years, unless earlier terminated or extended according to the terms of the transition services agreement. For the three months ended March 31, 2022, the Company recorded $3.6 million in other income reflecting services provided to bluebird bio and $0.6 million of operating expenses reflecting services received from bluebird bio, for activities related to the transition services. Additionally, under the transition services agreements, 2seventy bio is subleasing 30% of its headquarters at 60 Binney Street in Cambridge, Massachusetts to bluebird bio through the first quarter of 2022. Beginning in the second quarter of 2022, this percentage will decrease to 23% for the remainder of the year. The Company recorded $1.2 million in other income related to sublease income from bluebird under this arrangement during the three months ended March 31, 2022. As of March 31, 2022, amounts due to bluebird bio under the above agreements were $0.4 million and are included in accrued expenses. As of March 31, 2022, amounts due from bluebird bio under the above agreements were $6.5 million and are included in receivables and other current assets. Corporate allocations Prior to the separation, the Company did not operate as a separate, stand-alone entity, but rather was managed and operated in the normal course of business under bluebird bio. Accordingly, certain shared costs have been allocated to the Company and reflected as expenses in the Company's stand-alone condensed consolidated and combined financial statements for periods prior to the separation as described. The expenses reflected in the consolidated and combined financial statements may not be indicative of expenses that will be incurred by the Company in the future. For periods prior to the separation, the condensed consolidated and combined financial statements reflect allocations of certain expenses from bluebird bio, including, but not limited to, general corporate expenses, such as senior management, legal, human resources, accounting, other financial services (such as treasury, audit and purchasing), tax, information technology, and corporate employee benefits, incentives and stock-based compensation included within selling, general and administrative expense. These expenses have been allocated to the Company based on direct usage or benefit where specifically identifiable, with the remainder allocated based on employee time spent on projects, square footage or other measures that management believes are consistent and reasonable. Allocations for management costs and corporate support services provided to the Company totaled $19.9 million for the three months ended March 31, 2021. The financial information in these condensed consolidated and combined financial statements for periods prior to the separation does not necessarily include all the expenses that would have been incurred by the Company had it been a separate, stand-alone entity. Actual costs that may have been incurred if the Company had been a stand-alone company would depend on a number of factors, including the chosen organization structure and functions outsourced or performed by employees. See Note 2, Summary of significant accounting policies and basis of presentation , to the consolidated and combined financial statements included in the Company’s 2021 Annual Report on 10-K for additional information on the preparation and basis of presentation of these condensed consolidated and combined financial statements, including the treatment of certain research and development costs not directly attributable to individual programs. Usage of the Company's assets by bluebird bio and of bluebird bio's assets by the Company prior to separation Certain assets have been reflected in these condensed consolidated and combined financial statements as the underlying assets were assumed by the Company; however, bluebird bio has historically utilized a portion of the underlying asset as part of its operations. Accordingly, the expense related to the underlying asset has been reflected in the 2021 condensed consolidated and combined financial statements. The Company has also recorded an imputed charge to bluebird bio to reflect the cost of bluebird bio's proportional usage. In addition, the Company has recorded as an expense an imputed charge to reflect the cost of the Company's proportional usage of certain underlying assets not reflected in the condensed consolidated and combined financial statements but for which the Company has historically utilized a portion of the underlying asset as part of its operations. The income and expense recognized by the Company resulting from these imputed charges is recorded as other income, net in the 2021 condensed consolidated and combined financial statements and was as follows (in thousands): For the three months ended March 31, 2021 Imputed charge to bluebird bio for leases $ 4,465 Imputed charge from bluebird bio for leases (259) Imputed charge to bluebird bio for property, plant and equipment 528 Imputed charge from bluebird bio for property, plant and equipment (51) Imputed charge to bluebird bio for intangible assets 36 Other (1) $ 4,718 Other components of other income, net, that are not shown in the table above primarily include immaterial rental income and gains and losses on disposals of fixed assets. There are no such imputed charges in 2022 as the Company recognized all post separation income and costs related pursuant to the terms of the various transition agreements between the Company and bluebird bio, as discussed in previous section. Stock-based compensation As discussed in Note 12, Stock-based compensation , 2seventy bio’s employees participated in bluebird bio's stock-based compensation plans, the costs of which have been allocated to 2seventy bio and recorded in research and development and selling, general and administrative expenses in the condensed consolidated and combined statements of operations and comprehensive loss. Retirement plans 2seventy bio’s employees participated in bluebird bio's 401(k) Savings plan, the costs of which have been allocated to 2seventy bio and recorded in research and development and selling, general and administrative expenses in the condensed consolidated and combined statements of operations and comprehensive loss. Transaction costs Prior to the separation, bluebird bio had incurred costs related to the separation of the Company. To the extent separation costs were incurred that directly benefited the Company as a stand-alone company, such costs were allocated to the Company. Centralized cash management Prior to separation, no separate cash accounts for 2seventy bio were maintained and, therefore, bluebird bio was presumed to have funded 2seventy bio’s operating, investing and financing activities as necessary. As cash was disbursed and received by bluebird bio, for purposes of the condensed consolidated and combined financial statements, funding of 2seventy bio’s expenditures was reflected in the condensed consolidated and combined financial statements as a component of net parent investment.

Income taxes

Income taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Income taxesDeferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands): For the three months ended March 31, 2022 2021 Outstanding stock options (1) 2,780 — Restricted stock units (1) 1,655 — ESPP shares and other 35 — 4,470 — (1) Outstanding stock options and restricted stock units include awards outstanding to employees of bluebird bio. As described further in Note 9, Stockholders’ equity , to the consolidated and combined financial statements included in the Company’s 2021 Annual Report on Form 10-K, in November 2021, the Company issued to certain

Summary of significant accoun_2

Summary of significant accounting policies and basis of presentation (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The Company did not operate as a separate, stand-alone entity prior to its separation from bluebird bio. Accordingly, the Company’s consolidated and combined statements of operations and comprehensive loss, stockholders’ equity and cash flows for the three months ended March 31, 2021, have been prepared on a carve out basis, derived from bluebird bio’s consolidated financial statements and accounting records. The accompanying condensed consolidated and combined financial statements reflect the historical results of the operations, financial position and cash flows of the Company and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as included in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The historical results of operations and cash flows of 2seventy bio presented in these condensed consolidated and combined financial statements for periods prior to the separation may not be indicative of what they would have been had 2seventy bio operated as an independent, stand-alone entity for those periods. The historical results of operations, financial position and cash flows of 2seventy bio presented in these condensed consolidated and combined financial statements for periods subsequent to the separation are not necessarily indicative of 2seventy bio's future results of operations, financial position and cash flows.
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates and judgments are used in the following areas, among others: allocations of revenue, expenses, assets and liabilities from bluebird bio's historical consolidated financial statements to the Company for periods prior to the separation, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.

Marketable securities (Tables)

Marketable securities (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Marketable Securities	The following table summarizes the marketable securities held at March 31, 2022 and December 31, 2021 (in thousands): Amortized Unrealized gains Unrealized losses Fair Value March 31, 2022 U.S. government agency securities and $ 140,192 $ 3 $ (2,028) $ 138,167 Corporate bonds 33,803 — (136) 33,667 Commercial paper 9,822 — — 9,822 Total $ 183,817 $ 3 $ (2,164) $ 181,656 December 31, 2021 U.S. government agency securities and $ 128,899 $ — $ (507) $ 128,392 Corporate bonds 49,368 — (58) 49,310 Commercial paper 54,065 — — 54,065 Total $ 232,332 $ — $ (565) $ 231,767

Fair value measurements (Tables

Fair value measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 (in thousands): Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) March 31, 2022 Assets: Cash and cash equivalents $ 270,893 $ 270,893 $ — $ — Marketable securities: U.S. government agency securities and treasuries 138,167 — 138,167 — Corporate bonds 33,667 — 33,667 — Commercial paper 9,822 — 9,822 — Total assets $ 452,549 $ 270,893 $ 181,656 $ — Liabilities: Contingent consideration $ 1,996 $ — $ — $ 1,996 Total liabilities $ 1,996 $ — $ — $ 1,996 December 31, 2021 Assets: Cash and cash equivalents $ 130,414 $ 130,414 $ — $ — Marketable securities: U.S. government agency securities and treasuries 128,392 — 128,392 — Corporate bonds 49,310 — 49,310 — Commercial paper 54,065 — 54,065 — Total assets $ 362,181 $ 130,414 $ 231,767 $ — Liabilities: Contingent consideration $ 1,948 $ — $ — $ 1,948 Total liabilities $ 1,948 $ — $ — $ 1,948
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value	The table below provides a roll-forward of fair value of the Company’s contingent consideration obligations that include Level 3 inputs (in thousands): For the three months ended March 31, 2022 Beginning balance $ 1,948 Additions — Changes in fair value 48 Payments — Ending balance $ 1,996

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment, Net	Property, plant and equipment, net, consists of the following (in thousands): As of March 31, 2022 As of December 31, 2021 Laboratory equipment $ 33,065 $ 31,710 Leasehold improvements 26,709 28,479 Office equipment 6,080 6,080 Construction-in-progress 5,515 3,462 Computer equipment and software 5,260 5,260 Total property, plant and equipment 76,629 74,991 Less accumulated depreciation and amortization (41,591) (40,078) Property, plant and equipment, net $ 35,038 $ 34,913

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Summary of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): As of March 31, 2022 As of December 31, 2021 Employee compensation $ 14,796 $ 24,655 Collaboration research costs 14,082 2,576 Manufacturing costs 11,097 5,459 Royalties 4,146 6,768 Professional fees 1,942 1,688 Clinical and contract research organization costs 1,938 3,229 Property, plant, and equipment 1,311 2,241 Separation related costs 818 762 Other 8,345 8,032 Total accrued expenses and other current liabilities $ 58,475 $ 55,410

Collaborative arrangements an_2

Collaborative arrangements and strategic partnerships (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Total Transaction Price, Allocation of Total Transaction Price to Identified Performance Obligations Under Arrangement and Amount of Transaction Price Unsatisfied	The following table summarizes the amounts associated with the research activities under the collaboration included in research and development expense or recognized as collaborative arrangement revenue for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Net expense $ (6,893) $ (16,825) Three Months Ended March 31, 2022 2021 ASC 606 ide-cel license and manufacturing revenue - ex-U.S. $ 2,790 $ 5,104
Changes in Balances of Company's Receivables and Contract Liabilities	The following table presents changes in the balances of the Company’s BMS receivables and contract liabilities during the three months ended March 31, 2022 (in thousands): Balance at December 31, 2021 Additions Deductions Balance at March 31, 2022 Receivables $ 652 $ — $ (652) $ — Contract liabilities: Deferred revenue $ 25,762 $ — $ — $ 25,762

Stock-based compensation (Table

Stock-based compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense by Award Type	Stock-based compensation expense recognized by award type was as follows (in thousands): For the three months ended March 31, 2022 2021 Stock options $ 4,404 $ 7,586 Restricted stock units 5,314 7,205 Employee stock purchase plan and other 21 2,318 $ 9,739 $ 17,109
Schedule of Stock-Based Compensation Expense by Classification	Stock-based compensation expense by classification included within the condensed consolidated and combined statements of operations and comprehensive loss was as follows (in thousands): For the three months ended March 31, 2022 2021 Research and development $ 4,218 $ 9,431 Selling, general and administrative 5,521 7,678 $ 9,739 $ 17,109

Related-party transactions (Tab

Related-party transactions (Tables)	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The income and expense recognized by the Company resulting from these imputed charges is recorded as other income, net in the 2021 condensed consolidated and combined financial statements and was as follows (in thousands): For the three months ended March 31, 2021 Imputed charge to bluebird bio for leases $ 4,465 Imputed charge from bluebird bio for leases (259) Imputed charge to bluebird bio for property, plant and equipment 528 Imputed charge from bluebird bio for property, plant and equipment (51) Imputed charge to bluebird bio for intangible assets 36 Other (1) $ 4,718

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share	The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands): For the three months ended March 31, 2022 2021 Outstanding stock options (1) 2,780 — Restricted stock units (1) 1,655 — ESPP shares and other 35 — 4,470 —

Description of the business - N

Description of the business - Narrative (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)employee	Mar. 31, 2021USD ($)
Subsequent Event [Line Items]
Conversion ratio	0.3333
Net loss	$ (85,711)	$ (87,196)
Net cash used in operating activities	(74,064)	$ (64,750)
Cash, cash equivalents, and marketable securities	$ 452,500
2seventy bio Securities Corporation
Subsequent Event [Line Items]
Number of employees | employee	0

Marketable securities - Summary

Marketable securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Amortized cost/ cost	$ 183,817	$ 232,332
Unrealized gains	3	0
Unrealized losses	(2,164)	(565)
Fair Value	181,656	231,767
U.S. government agency securities and treasuries
Marketable Securities [Line Items]
Amortized cost/ cost	140,192	128,899
Unrealized gains	3	0
Unrealized losses	(2,028)	(507)
Fair Value	138,167	128,392
Corporate bonds
Marketable Securities [Line Items]
Amortized cost/ cost	33,803	49,368
Unrealized gains	0	0
Unrealized losses	(136)	(58)
Fair Value	33,667	49,310
Commercial paper
Marketable Securities [Line Items]
Amortized cost/ cost	9,822	54,065
Unrealized gains	0	0
Unrealized losses	0	0
Fair Value	$ 9,822	$ 54,065

Fair value measurements - Recor

Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets:
Marketable securities:	$ 181,656	$ 231,767
U.S. government agency securities and treasuries
Assets:
Marketable securities:	138,167	128,392
Corporate bonds
Assets:
Marketable securities:	33,667	49,310
Commercial paper
Assets:
Marketable securities:	9,822	54,065
Fair value, measurements, recurring
Assets:
Cash and cash equivalents	270,893	130,414
Total assets	452,549	362,181
Liabilities:
Contingent consideration	1,996	1,948
Total liabilities	1,996	1,948
Fair value, measurements, recurring | U.S. government agency securities and treasuries
Assets:
Marketable securities:	138,167	128,392
Fair value, measurements, recurring | Corporate bonds
Assets:
Marketable securities:	33,667	49,310
Fair value, measurements, recurring | Commercial paper
Assets:
Marketable securities:	9,822	54,065
Fair value, measurements, recurring | Quoted prices in active markets (Level 1)
Assets:
Cash and cash equivalents	270,893	130,414
Total assets	270,893	130,414
Liabilities:
Contingent consideration	0	0
Total liabilities	0	0
Fair value, measurements, recurring | Quoted prices in active markets (Level 1) | U.S. government agency securities and treasuries
Assets:
Marketable securities:	0	0
Fair value, measurements, recurring | Quoted prices in active markets (Level 1) | Corporate bonds
Assets:
Marketable securities:	0	0
Fair value, measurements, recurring | Quoted prices in active markets (Level 1) | Commercial paper
Assets:
Marketable securities:	0	0
Fair value, measurements, recurring | Significant other observable inputs (Level 2)
Assets:
Cash and cash equivalents	0	0
Total assets	181,656	231,767
Liabilities:
Contingent consideration	0	0
Total liabilities	0	0
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | U.S. government agency securities and treasuries
Assets:
Marketable securities:	138,167	128,392
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Corporate bonds
Assets:
Marketable securities:	33,667	49,310
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Commercial paper
Assets:
Marketable securities:	9,822	54,065
Fair value, measurements, recurring | Significant unobservable inputs (Level 3)
Assets:
Cash and cash equivalents	0	0
Total assets	0	0
Liabilities:
Contingent consideration	1,996	1,948
Total liabilities	1,996	1,948
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | U.S. government agency securities and treasuries
Assets:
Marketable securities:	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Corporate bonds
Assets:
Marketable securities:	0	0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Commercial paper
Assets:
Marketable securities:	$ 0	$ 0

Fair value measurements - Narra

Fair value measurements - Narrative (Detail)	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value Disclosures [Abstract]
Interest receivable	$ 300,000
Interest receivable, write-off	$ 0

Fair value measurements - Roll-

Fair value measurements - Roll-Forward of Fair Value of the Company's Contingent Consideration Obligations (Detail) - Significant unobservable inputs (Level 3) - Contingent consideration obligations $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,948
Additions	0
Changes in fair value	48
Payments	0
Ending balance	$ 1,996

Property, plant and equipment_3

Property, plant and equipment, net - Summary of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 76,629	$ 74,991
Less accumulated depreciation and amortization	(41,591)	(40,078)
Property, plant and equipment, net	35,038	34,913
Laboratory equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	33,065	31,710
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	26,709	28,479
Office equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	6,080	6,080
Construction-in-progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	5,515	3,462
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 5,260	$ 5,260

Property, plant and equipment_4

Property, plant and equipment, net - Narrative (Detail) $ in Millions	Sep. 30, 2021USD ($)
Lentiviral Vector Manufacturing Facility
Property, Plant and Equipment [Line Items]
Net assets disposed of	$ 111.2

Accrued expenses and other cu_3

Accrued expenses and other current liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Employee compensation	$ 14,796	$ 24,655
Collaboration research costs	14,082	2,576
Manufacturing costs	11,097	5,459
Royalties	4,146	6,768
Professional fees	1,942	1,688
Clinical and contract research organization costs	1,938	3,229
Property, plant, and equipment	1,311	2,241
Separation related costs	818	762
Other	8,345	8,032
Total accrued expenses and other current liabilities	$ 58,475	$ 55,410

Commitments and contingencies -

Commitments and contingencies - Narrative (Detail) $ in Millions	1 Months Ended
	Jul. 31, 2021USD ($)batchagreement	Mar. 31, 2022USD ($)
Resilience
Commitments And Contingencies Disclosure [Line Items]
Number of manufacturing agreements | agreement	2
Net operating losses, percentage of reimbursement	50.00%
Reimbursement cap	$ 15
Accrued Liabilities		$ 8
Net operating losses, percentage of minimum purchase amount	50.00%
Maximum | Resilience
Commitments And Contingencies Disclosure [Line Items]
Number of lentiviral vector batches | batch	8
Pregenen
Commitments And Contingencies Disclosure [Line Items]
Contingent future cash payments		$ 99.9

Collaborative arrangements an_3

Collaborative arrangements and strategic partnerships - Narrative (Detail) $ / shares in Units, $ in Thousands, shares in Millions	Aug. 24, 2018USD ($)accounting_unit$ / sharesshares	Jul. 31, 2021USD ($)batchagreement	Aug. 31, 2018target	Mar. 31, 2022USD ($)performance_obligation	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 23, 2021USD ($)performance_obligation	Mar. 31, 2020USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Income (loss) from collaborative arrangements				$ (5,352)	$ 0
Number of performance obligations | performance_obligation				2
Number of accounting units | accounting_unit	2
Lentiviral Vector Manufacturing Facility | Bluebird Bio
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from divestiture of business		$ 110,300
Bristol-Myers Squibb
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Income (loss) from collaborative arrangements				$ 5,400	0
Collaboration agreement, transaction price				31,000
Estimated variable consideration				1,800
Contract with customer liability				25,762		$ 25,762
Bristol-Myers Squibb | Phase I, Additional Obligation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Estimated variable consideration								$ 27,400
Bristol-Myers Squibb | Research and development services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Estimated variable consideration								$ 5,400
Bristol-Myers Squibb | bb21217 license agreement | U.S.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional fee receivable if option to co-develop and co-promote is not exercised				10,000
Bristol-Myers Squibb | Bb Two One Two One Seven License And Manufacturing Services | License and manufacturing services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract with customer liability				25,800		25,800
Regeneron Collaboration Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of initial collaboration targets | target			6
Research collaboration term			5 years
Joint research activities remaining to be recognized				19,800		$ 23,300
Regeneron Collaboration Agreement | Collaboration
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue balance recognized as gross revenues				3,500	$ 1,500
Regeneron Collaboration Agreement | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable	$ 130,000
Regeneron Collaboration Agreement | Research and development services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration agreement, transaction price	100,000
Purchase price premium	$ 37,000
Collaborative arrangement amortization period	5 years
Collaborative arrangement amount attributed to joint research activities	$ 45,500
Regeneron Collaboration Agreement | Research and development services | Bluebird Bio
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement amount attributed to equity sold	$ 54,500
Regeneron Collaboration Agreement | Share purchase agreement | Bluebird Bio
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock price per share (in dollars per share) | $ / shares	$ 238.10
Investment in common stock	$ 100,000
Purchase price premium	$ 37,000
Collaborative arrangement research initial funding obligation, percentage	50.00%
Regeneron Collaboration Agreement | Share purchase agreement | Common stock | Bluebird Bio
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock to Regeneron (in shares) | shares	0.4
Investment in common stock	$ 63,000
Resilience
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of manufacturing agreements | agreement		2
Net operating losses, percentage of reimbursement		50.00%
Reimbursement cap		$ 15,000
Net operating losses, percentage of minimum purchase amount		50.00%
Resilience | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of lentiviral vector batches | batch		8
Novo Nordisk A/S | Novo Collaboration and License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Estimated variable consideration				11,700
Number of performance obligations | performance_obligation							2
Contract with customer liability							$ 5,000
Estimated variable consideration, research reimbursement				6,700
Estimated variable consideration, upfront payment				5,000
Revenue				$ 1,300
Novo Nordisk A/S | Novo Collaboration and License Agreement | License and manufacturing services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable							26,000
Novo Nordisk A/S | Novo Collaboration and License Agreement | Development and Commercialization Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable							72,000
Novo Nordisk A/S | Novo Collaboration and License Agreement | Scientific Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable							15,000
Novo Nordisk A/S | Novo Collaboration and License Agreement | Extension of Research Plan without Achieving Scientific Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable							$ 9,000

Collaborative arrangements an_4

Collaborative arrangements and strategic partnerships - Summary of Revenue Recognized or Expense Incurred for Joint Ide-cel Development Efforts Related to Combined Unit of Accounting for its License and Vector Manufacturing of Ide-cel (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense	$ (69,245)	$ (77,571)
Bristol-Myers Squibb | U.S. | Ide-cel Research And Development Services | License and manufacturing services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense	(6,893)	(16,825)
Bristol-Myers Squibb | Outside of U.S. | Ide-cel license and manufacturing services | License and manufacturing services
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 2,790	$ 5,104

Collaborative arrangements an_5

Collaborative arrangements and strategic partnerships - Changes in Balances of Company's Receivables and Contract Liabilities (Detail) - Bristol-Myers Squibb $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Receivables
Balance at December 31, 2021	$ 652
Additions	0
Deductions	(652)
Balance at March 31, 2022	0
Contract liabilities:
Balance at December 31, 2021	25,762
Additions	0
Deductions	0
Balance at March 31, 2022	$ 25,762

Royalty and other revenue - Add

Royalty and other revenue - Additional Information (Detail) - Royalty and other revenue - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
License And Royalty Revenue [Line Items]
Revenue	$ 887	$ 4,464
Juno Therapeutics | Bluebird Bio
License And Royalty Revenue [Line Items]
Revenue		$ 2,500

Equity - Narrative (Details)

Equity - Narrative (Details) - Private Placement $ / shares in Units, $ in Millions	1 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Subsidiary, Sale of Stock [Line Items]
Number of shares issued in transaction (in shares) | shares	13,934,427
Common stock price per share (in dollars per share) | $ / shares	$ 12.20
Proceeds from issuance of common stock | $	$ 165.7

Stock-based compensation - Summ

Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 9,739	$ 17,109
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4,404	7,586
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	5,314	7,205
Employee stock purchase plan and other
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 21	$ 2,318

Stock-based compensation - Sche

Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 9,739	$ 17,109
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4,218	9,431
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 5,521	$ 7,678

Stock-based compensation - Narr

Stock-based compensation - Narrative (Detail)	3 Months Ended
	Mar. 31, 2022shares
2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period (less than) (in shares)	0

Related-party transactions - Na

Related-party transactions - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2022	Nov. 03, 2021agreement
Related Party Transaction [Line Items]
Operating income (loss)	$ (90,588)	$ (92,370)
Costs and expenses	99,017	104,271
Number of transition services agreements | agreement				2
Transition services agreement, initial term				2 years
Other income, net	4,762	5,174
Bluebird Bio | Management Costs and Corporate Support Services
Related Party Transaction [Line Items]
Allocations for management costs and corporate support services provided to the Company		$ 19,900
Bluebird Bio | Separation Agreement
Related Party Transaction [Line Items]
Operating income (loss)	2,900
Costs and expenses	200
Bluebird Bio | Transition Services Agreement
Related Party Transaction [Line Items]
Costs and expenses	600
Other income, net	$ 3,600
Area of sublease, percent	30.00%
Sublease income	$ 1,200
Due to related parties	400
Due from related parties	$ 6,500
Bluebird Bio | Transition Services Agreement | Scenario, Forecast
Related Party Transaction [Line Items]
Area of sublease, percent			23.00%

Related Party Disclosures - Imp

Related Party Disclosures - Imputed Charges (Details) - Bluebird Bio $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	$ 4,718
Imputed charge to bluebird bio for leases
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	4,465
Imputed charge from bluebird bio for leases
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	(259)
Imputed charge to bluebird bio for property, plant and equipment
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	528
Imputed charge from bluebird bio for property, plant and equipment
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	(51)
Imputed charge to bluebird bio for intangible assets
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	36
Other
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction	$ (1)

Net Loss Per Share - Common Sto

Net Loss Per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares)	4,470,000	0
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares)	2,780,000	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares)	1,655,000	0
ESPP shares and other
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares)	35,000	0

Net Loss Per Share - Narrative

Net Loss Per Share - Narrative (Details) - Pre-funded Warrants - Private Placement	Nov. 30, 2021$ / sharesshares
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Pre-funded warrants issued (in shares) | shares	757,575
Exercise price of warrants (in dollars per share) | $ / shares	$ 0.0001